L
Luigi Pusterla
Publications - 11
Citations - 446
Luigi Pusterla is an academic researcher. The author has contributed to research in topics: Adverse effect & Prospective cohort study. The author has an hindex of 8, co-authored 9 publications receiving 423 citations.
Papers
More filters
Journal ArticleDOI
Incidence of adverse reactions in HIV patients treated with protease inhibitors : A Cohort Study
Paolo Bonfanti,Laura Valsecchi,Fabio Parazzini,Silvia Carradori,Luigi Pusterla,Fortuna P,Timillero L,Federica Alessi,Giancarlo Ghiselli,Andrea Gabbuti,Elisabetta Di Cintio,Canio Martinelli,Ivano Faggion,Simona Landonio,Tiziana Quirino +14 more
TL;DR: Ritonavir is the drug associated with the largest number of reactions, which appear during the first few months of treatment, and Saquinavir HGC and nelfinavir are the best tolerated drugs in a clinical setting.
Journal ArticleDOI
HIV and metabolic syndrome: a comparison with the general population.
Paolo Bonfanti,Cristina Giannattasio,Elena Ricci,Rita Facchetti,Elena Rosella,M. Franzetti,Laura Cordier,Luigi Pusterla,Michele Bombelli,Roberto Sega,Tiziana Quirino,Giuseppe Mancia +11 more
TL;DR: The risk of MS is greater in HIV-infected patients compared with the general population because of a greater prevalence of lipid and glucose abnormalities.
Journal ArticleDOI
Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group.
Paolo Bonfanti,Laura Valsecchi,Fabio Parazzini,Silvia Carradori,Luigi Pusterla,Fortuna P,Timillero L,Alessi F,Ghiselli G,Andrea Gabbuti,Di Cintio E,Canio Martinelli,Ivano Faggion,Simona Landonio,Tiziana Quirino +14 more
TL;DR: Ritonavir is the drug associated with the largest number of reactions, which appear during the first few months of treatment, and Saquinavir HGC and nelfinavir are the best tolerated drugs in a clinical setting.
Journal ArticleDOI
HAART tolerability: post-exposure prophylaxis in healthcare workers versus treatment in HIV-infected patients.
Tiziana Quirino,Fosca Niero,Elena Ricci,Luigi Pusterla,Silvia Carradori,Andrea Gabbuti,E Iemoli,Simona Landonio,Ivano Faggion,Paolo Bonfanti +9 more
TL;DR: It is shown that treatment interruption is eight times higher in HIV-negative subjects compared to HIV-seropositive patients, and that the incidence of adverse events is approximately six times higher, though such events, are for the most part, not severe.
Journal ArticleDOI
The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: a randomized multicentric study
Paolo Bonfanti,Luigi Pusterla,Fabio Parazzini,Marco Libanore,A.E. Cagni,M. Franzetti,Ivano Faggion,Simona Landonio,Tiziana Quirino +8 more
TL;DR: In this article, the authors evaluated if desensitization treatment is more effective than rechallenge in preventing hypersensitivity reactions in HIV-positive patients with previous allergic reactions to TMP-SMX.